Traveler’s Infections: Understanding SARS-CoV-2 as a Potential Agent

Victor B. Oti, Marina Ioannou

Abstract


Coronavirus disease 2019 (COVID-19) has become a major, global, public health challenge. More than 1,051,635 confirmed cases (and counting) have been reported worldwide, thus far, and both local and international travelers are considered to represent populations at high risk of acquiring the infection. Many factors are involved in the spread of this viral agent, including travel to and from endemic areas, a history of contact with a traveler from an endemic country, the virus infection rate at the destination, individual health, and inadequate prevention and control measures. COVID-19 symptoms range from fever and cough to difficulty breathing, and more severe cases can present with pneumonia and multi-organ failure. The virus is thought to be transmitted through large respiratory droplets, generated by coughing or sneezing and transmitted through close contact with infected persons or contaminated surfaces. Diagnostic strategies include the assays for the detection of antiviral antibodies, multiplex nucleic acid amplification, and microarray-based assays. Currently, no approved antiviral therapy or vaccine exists to treat or prevent the infection. Public health measures, such as quarantine, have been enforced, to slow the community spread of the virus, by governments, worldwide. The World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) have recommended COVID-19 infection screening be performed at airports, for all travelers, before traveling to endemic countries and the restriction of travel to countries more than one thousand cases of infection. In response to the global outbreak, this review examines COVID-19 as a potential traveler’s infection.

Keywords


COVID-19, pandemic, SARS-CoV-2, travelers, viral agent

Full Text:

PDF

References


 1. Adhikari SP, Meng S, Wu Y, Mao Y, Ye R, Wang Q, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infectious Diseases of Poverty. 2020; 9: 29.

 2. World Health Organization. Novel coronavirus - China [WWW Document]. URL https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/ (accessed 4.2.20).2020a

 3. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nature Reviews Microbiology. 2019; doi:10.1038/s41579-018-0118-9

 4. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. (2020). Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding, Lancet395, 2020; 565–574,

 5. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 1–4, doi:10.1038/s41586-020-2012-7.

 6. Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, et al. Virology, epidemiology, pathogenesis and control of COVID-19. Viruses. 2020a; 12: 372.

 7. World Health Organization. 2019- nCoV Situation Report-22 on 12 February, 2020. https://www.who.int/docs/defaultsource/coronaviruse/situation-reports/2020b

 8. Rothan HA and Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19). Journal of Autoimmunity (In Press), 2020.https://doi.org/10.1016/j.jaut.2020.102433

 9. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation. bioRxiv, 2020; doi:10.1101/2020.02.11.944462.

 10. Tang X, Wu C, Li X, Song Y, Yao X, Wu X, et al. (2020a). On the origin and continuing evolution of SARS-CoV-2. Natl. Sci. Rev. 2020a; doi:10.1093/nsr/nwaa036.

 11. Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nature Microbiology, 2020; 1–8.

 12. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet 395, 2020b; 565–574. doi:10.1016/S0140-6736(20)30251-8

 13. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. International Journal of Antimicrobial Agents. 2020; 55 (3): 105924.

 14. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; published online Jan 29, https://doi.org/10.1016/ S01406736(20)30211-7

 15. Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. International Journal of Oral Science. 2020; 12 (1): 8.

 16. Lu G, Wang Q, Gao GF. Bat-to-human: spike features determining ‘host jump’ of coronaviruses SARS-CoV, MERS-CoV, and beyond. Trends in Microbiology. 2015; 23: 468–478. doi:10.1016/J.TIM.2015.06.003

 17. Wang Q, van der Velde R, Su Z, Wen J. Aquarius L-band scatterometer and radiometer observations over a Tibetan Plateau site. International Journal of Applied Earth Observation and Geoinformation. 2016; 45:165–177. doi:10.1016/j.jag.2015.06.010

 18. World Health Organization. Novel Coronavirus (2019-nCoV) Situation Report-11. 2020c.

 19. Sahin AR, Erdogan A, MutluAgaoglu P, Dineri Y, Cakirci AY, Senel ME, et al. 2019 Novel Coronavirus (COVID-19) Outbreak: A Review of the Current Literature. EJMO, 2020; 4(1):1-7.DOI: 10.14744/ejmo.2020.12220.

 20. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Medicine. 2020a;doi:10.1007/s00134-020-05985-9.

 21. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. New England Journal of Medicine. 2020; 382, 970–971. doi:10.1056/NEJMc2001468

 22. Zhang W, Du RH, Li B, Zheng XS, Yang XL, Hu B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes.Emerging Microbes & Infections. 2020b;9 (1): 386–389.

 23. Lei J, Li J, Li X, Qi X. CT imaging of the 2019 novel coronavirus (2019-nCoV) pneumonia. Radiology. 2020; 200236, https://doi.org/10.1148/radiol. 2020200236.

 24. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020; Published onlineJanuary23,2020. doi:10.2807/1560-7917.ES.2020.25.3.2000045

 25. Huang C, Wang Y, Li X, Ren L, Zhou J, Hu Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 2020; (10223).497–506.

 26. Gralinski LE, Menachery VD. Return of the coronavirus: 2019-nCoV. Viruses.2020;12:135.

 27. Hoehl S, Berger A, Kortenbusch M, Cinatl J, Bojkova D, Rabenau H, et al. Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China. N.Engl. J. Med. 2020; doi:10.1056/NEJMc2001899.

 28. Centre for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19) Symptoms".Centers for Disease Control and Prevention. United States. 10 February 2020. Archived from the original on 30 January 2020, 2020b.

 29. Zhu N, Zhang D, Wang W.et al. A novel coronavirus from patients with pneumonia in China, 2019. N England J Medicine. 2020; Publish online Jan 29. DOI: 10.1056/NEJMoa2001017

 30. Du Toit A. Outbreak of a novel coronavirus, Nat. Rev. Microbiol. 2020; 18 (123) (2020), https://doi.org/10.1038/s41579-020-0332-0.

 31. World Health Organization. Novel Coronavirus (2019-nCoV) Situation Report-11, 2020e.

 32. World Health Organization. 2019- nCoV Situation Report-22 on 12 February, 2020. https://www.who.int/docs/defaultsource/coronaviruse/situation-reports/ 2020f

 33. Fan J, Liu X, Pan W, Douglas MW, Bao S. Epidemiology of 2019 Novel Coronavirus Disease-19 in Gansu Province, China, 2020.Emerging Infectious Diseases. 2020; 26. doi:10.3201/eid2606.200251

 34. Giovanetti M, Benvenuto D, Angeletti S, Ciccozzi M. The first two cases of 2019‐nCoV in Italy: Where they come from? Journal of Medical Virology. 2020; 92, 518–521. doi:10.1002/jmv.25699

 35. Walter S. Japan confirms first case of infection from Wuhan coronavirus; Vietnam quarantines two tourists, The Straight Times, January 16, 2020, https://www. straitstimes.com/asia/east-asia/japan-confirms-first-case-of infection- with-new-china-coronavirus

 36. First confirmed case of novel coronavirus in Australia,25 January 2020,https://www.health.gov.au/ministers/the-hon-greg-hunt-mp/media/first-confirmed-case-of-novel-coronavirus-in-australia

 37. Michelle LH, Chas DB, Scott L, Kathy HL, John W, Hollianne B, et.al, First Case of 2019 Novel Coronavirus in the United States. The New England Journal of Medicine. 2020; 382:929-936,DOI: 10.1056 /NEJMoa2001191

 38. Vincent W. Coronavirus: France confirms three cases of deadly virus, Independent, 24 January 2020, https://www. Independent .co.uk /news /world /europe/coronavirus-france-china-wuhan-virus-symptoms-outbreak-latest-a9301106.html

 39. Robin W. The New Yorker, How Iran Became a New Epicenter of the Coronavirus Outbreak, February 28, 2020,https://www.newyorker.com/news/our-columnists/how-iran-became-a-new-epicenter-of-the-coronavirus-outbreak

 40. Ariba S. Two coronavirus cases confirmed in Pakistan, Pakistan Today, February 27, 2020,https://www.pakistantoday.com.pk/2020/02/26/sindh-health-two-coronavirus-cases-confirmed-in-pakistan-confirms-first-coronavirus-case-in-karachi/

 41. Daily S. Turkey remains firm, calm as first coronavirus case confirmed, 11 March 2020,https://www.dailysabah.com/turkey/turkey-remains-firm-calm-as-first-coronavirus -case-confirmed/news

 42. Popo M. First case of Covid-19 Coronavirus reported in SA,5 Mar 2020,https://www.gov.za/speeches/health-reports-first-case-covid-19-coronavirus-5-mar-2020-0000

 43. World Health Organization. Novel Coronavirus (2019-nCoV) Advice for the Public: Myth Buster; https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/myth-busters (23 March 2020). 2020h

 44. World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report-71. 2020i

 45. Wang C, Horby PW, Harden FG, Gao GF. A novel coronavirüs outbreak of global health concern. Lancet. 2020c; publish online Jan 24, https://doi.org/10.1016/S0140-6736(20)30185-9

 46. Centre for Disease Control and Prevention. Coronavirus disease-19. How to protect yourself. 2020. Sheet 2, 2020c.

 47. Centre for Disease Control and Prevention. First travel-related case of 2019 novel coronavirus detected in United States, January 21, 2020, 2020d. https://www.cdc.gov/media/releases/2020/p0121-novel-coronavirus-travel-case.html (Accessed on January 21, 2020).

 48. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci. Trends. 2020; https://doi.org/10.5582/bst.2020.01020.

 49. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. The New England Journal of Medicine. 2020;doi:10.1056/NEJMoa2001282.

 50. Li G, De Clercq E Therapeutic options for the 2019 novel coronavirus (2019-nCoV).Nature Reviews. Drug Discovery. 2020;19 (3): 149–150.

 51. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).Clinical Infectious Diseases. 2020;doi:10.1093/cid/ciaa237

 52. Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother. pii: 2020; AAC.00399-20. doi: 10.1128/AAC.00399-20.

 53. Bao L, Deng W, Huang B, Gao H, Liu J, Ren L, et al. The Pathogenicity of SARS-CoV-2 in hACE2 Transgenic Mice. bioRxiv, 2020; doi:10.1101/2020.02.07.939389.

 54. Duddu P. Coronavirus outbreak: Vaccines/drugs in the pipeline for Covid-19". Clinicaltrialsarena.com.Archived from the original on 19 February 2020, 2020.

 55. NhuThao TT, Labroussaa F, Ebert N, V’kovski P, Stalder H, Portmann J, et al. Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform. bioRxiv, 2020; doi:10.1101/2020.02.21.959817.




DOI: http://dx.doi.org/10.21109/kesmas.v15i2.3974

Refbacks

  • There are currently no refbacks.